Trial Profile
A Phase I/II, Open-Label, Uncontrolled, Dose-Escalation Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 07 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 24 May 2013 The results of this trial were included in an application for marketing approval of enzalutamide in Japan, according to a media release from Astellas and Medivation.